Racura Oncology (ASX:RAC) Pretax Margin %: % (As of Dec. 2025)


ASX:RAC Racura Oncology Ltd ASX:RAC
31 GF Score
Price A$2.21
View Full Analysis

What is Racura Oncology Pretax Margin %?

Racura Oncology ASX:RAC -5.96% 31 Pretax Margin % is % as of Dec. 2025. GuruFocus rates ASX:RAC with a GF Score™ of 31/100. Among 946 Biotechnology companies, Racura Oncology ranks worse than 105708.14% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Racura Oncology's Pre-Tax Income for the six months ended in Dec. 2025 was A$-4.10 Mil. Racura Oncology's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Racura Oncology's pretax margin for the quarter that ended in Dec. 2025 was %.

The historical rank and industry rank for Racura Oncology's Pretax Margin % or its related term are showing as below:


ASX:RAC's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.5
* Ranked among companies with meaningful Pretax Margin % only.

Racura Oncology  (ASX:RAC) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Racura Oncology Pretax Margin % Related Terms

Racura Oncology Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Racura Oncology's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Racura Oncology Pretax Margin % Chart

Racura Oncology Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Racura Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:RAC vs VRTX, REGN, ALNY: Pretax Margin % Comparison

For the Biotechnology subindustry, Racura Oncology's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Racura Oncology Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Racura Oncology's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Racura Oncology's Pretax Margin % falls into.


ASX:RAC
31GF Score
Racura Oncology Ltd ASX:RAC
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Racura Oncology Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Racura Oncology's Pretax Margin for the fiscal year that ended in Jun. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-4.787/0
= %

Racura Oncology's Pretax Margin for the quarter that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-4.099/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of % mean?
Racura Oncology (ASX:RAC) has a Pretax Margin % of % as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Racura Oncology and its competitors. According to the industry distribution chart, Racura Oncology ranks #999999 out of 946 companies in the Biotechnology industry.
Is Racura Oncology's Pretax Margin % too high?
Racura Oncology's current Pretax Margin % is %. Based on the distribution chart, Racura Oncology ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Racura Oncology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Racura Oncology's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Racura Oncology ranks #999999 out of 946 companies for Pretax Margin %. This places Racura Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Racura Oncology and its competitors. Racura Oncology's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Racura Oncology stock overvalued right now?
Racura Oncology (ASX:RAC) has a current Pretax Margin % of %. The current Pretax Margin % is %. Racura Oncology's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Racura Oncology (ASX:RAC), the current Pretax Margin % is % as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Racura Oncology Business Description

Other Exchanges FN3:Germany
Address 1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
31GF Score

Get the complete analysis for ASX:RAC

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.21
Price